ARTICLES BY JEREMY SCHAFER
-
Shifting Site Of Care For Infused Drugs: An Opportunity For Biosimilars3/3/2020
An emerging target for payers is how IV drugs are distributed to providers and where these products are administered. Site of care strategies can generate cost savings, but they may also create unintended consequences. However, just as biosimilars have disrupted the status quo of the biologics market, they may also find opportunity in impacting how care is delivered.
-
Adapting Clinical Trials For The Upcoming Oncology Value Wave6/8/2017
In 2015, an estimated $107 billion was spent globally on oncology therapeutics, a year-over-year increase of 11.5 percent. Drug spend reports from leading U.S. pharmacy benefit managers and payers found similar trends in 2016.
This website uses cookies to ensure you get the best experience on our website. Learn more